Acumen Pharmaceuticals (ABOS) Expected to Announce Earnings on Tuesday

Key Points

• Acumen Pharmaceuticals is set to announce its Q2 2025 earnings on August 12, 2025, with analysts predicting a loss of ($0.54) per share.
• The company reported a smaller-than-expected loss of ($0.48) EPS last quarter, exceeding analysts’ estimates of ($0.56) by $0.08.
• Citigroup has initiated coverage on Acumen Pharmaceuticals with a "buy" rating and a price target of $4.00 per share.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.54) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.08. During the same quarter last year, the company posted ($0.25) EPS. On average, analysts expect Acumen Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acumen Pharmaceuticals Price Performance

ABOS traded down $0.03 during midday trading on Friday, hitting $1.40. The company had a trading volume of 29,755 shares, compared to its average volume of 333,308. Acumen Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $3.36. The firm's 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.23. The company has a market capitalization of $84.50 million, a PE ratio of -0.72 and a beta of 0.14. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.02 and a current ratio of 8.02.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Acumen Pharmaceuticals stock. AQR Capital Management LLC acquired a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,735 shares of the company's stock, valued at approximately $46,000. AQR Capital Management LLC owned 0.07% of Acumen Pharmaceuticals at the end of the most recent reporting period. 71.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Citigroup assumed coverage on Acumen Pharmaceuticals in a research report on Tuesday, June 17th. They issued a "buy" rating and a $4.00 price objective on the stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.